ENO Bio has established mRNA targeted delivery capabilities based on widely used commercial LNPs, meeting common client needs for liver- or spleen-directed delivery in mRNA product development.

Building on this foundation, we have further developed proprietary LNP delivery systems and ligand-mediated mRNA delivery systems (non-LNP based). These platforms enable targeted mRNA delivery to multiple tissues and organs, including the liver, spleen, central nervous system, tumors, bone joints, heart, and skin, supporting both systemic and localized administration strategies for diverse clinical applications.

Concurrently, ENO Bio is actively advancing novel LNP and non-LNP targeting technologies for lung-, brain-, and in vivo immune cell-specific delivery. These efforts provide a technical foundation for clients developing innovative therapeutics with significant market potential, such as in vivo CAR-X, treatments for brain disorders, and pulmonary disease therapeutics.